This clinical trial is focused on studying the effectiveness of a medication called certolizumab pegol in women who experience recurrent implantation failure. Recurrent implantation failure refers to the situation where a woman is unable to achieve a clinical pregnancy after multiple attempts of transferring good-quality embryos. The trial aims to determine if certolizumab pegol can improve the chances of achieving a clinical pregnancy compared to a placebo.

Participants in the study will receive either certolizumab pegol or a placebo through a subcutaneous injection, which means the medication is injected under the skin. The study will monitor the participants over a period to assess the occurrence of a clinical pregnancy, which is confirmed by detecting a heartbeat in an ultrasound scan around five weeks of pregnancy. The study will also observe other outcomes such as live birth rates, miscarriages, and any potential side effects or complications during the pregnancy.

In addition to certolizumab pegol, the study will use sodium chloride as a solution for infusion, which is a common practice in clinical trials to ensure the safety and comfort of participants. The trial is designed to provide valuable insights into whether certolizumab pegol can be a beneficial treatment for women facing unexplained difficulties in achieving pregnancy through embryo transfer. The study is expected to continue until 2029, allowing for comprehensive data collection and analysis.